Infliximab的中國市場(2022年～2031年)

中國的Infliximab的銷售額，2017年～2021年之間約成長19.0％，2021年達成3億3,589萬人民幣。

由於中國政府實施嚴格的COVID-19清零政策，中國的Infliximab的銷售量和銷售額預計2022年減少。可是，2023年初以後，預計COVID-19管理政策緩和，2023年～2026年將顯出復甦成長。

本報告提供中國的Infliximab市場相關調查分析，市場COVID-19影響，市場規模，廠商分析，市場預測等資訊。

第1章 Infliximab的相關概念

• Infliximab的適應症
• 中國的Infliximab的開發
• 中國的Infliximab的政府核准
• COVID-19對中國的Infliximab銷售的影響

第2章 中國的Infliximab的銷售額(2017年～2021年)

• Infliximab的銷售額
  • 整體銷售額
  • 各地區的銷售額
• Infliximab的銷售量
  • 整體銷售量
  • 各地區的銷售量
• 中國的Infliximab的銷售:各投藥法(2017年～2021年)
  • 注射
  • 其他投藥法的分析

第3章 中國的主要Infliximab製造商分析(2017年～2021年)

• 主要的Infliximab製造商市場佔有率分析
  • 市場佔有率調查:各銷售額
  • 市場佔有率調查:各銷售量
• Janssen Biologics BV
  • 企業簡介
  • 中國的REMICADE(Janssen 公司的Infliximab)的銷售

第4章 中國的各種製造商Infliximab的價格(2021年～2022年)

• Janssen Biologics BV (REMICADE)

第5章 中國的Infliximab藥市場預測(2022年～2031年)

• 中國的Infliximab市場開發的影響因素
  • COVID-19對中國的Infliximab市場的影響
  • 推動市場要素和機會
  • 市場威脅與課題
• 市場規模的預測
• 市場趨勢的預測

Infliximab is a human-mouse chimeric IgG1 monoclonal antibody targeting tumor necrosis factor (TNF-α) (composed of human IgG1 constant region and mouse variable region). It is used to treat a variety of autoimmune diseases, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis. Infliximab was developed by Johnson & Johnson. In 2007, Infliximab entered the Chinese market. The Chinese infliximab market is completely dominated by Janssen, a Johnson & Johnson company, until 2021. Two local Chinese companies, Taizhou Mabtech Pharmaceutical Co., Ltd. and Hisun Biopharmaceutical Co., Ltd. are launching infliximab in 2021, making Janssen's infliximab a challenge in the Chinese market.

According to CRI's market research, since Infliximab entered the Chinese market in 2007, its sales have had an increasing trend. However, the sales in China are suboptimal compared to global sales. The main reason is that most patients in China cannot afford the expensive price. After Infliximab was included in the national medical insurance in 2019, the sales increased about 18.9% in 2020 and reached CNY335.89 million in 2021. The CAGR of infliximab's sales value in China is approximately 19.0% from 2017 to 2021.

According to CRI's market research and expert interviews, CRI sees different trends in 2022 and from 2023 to 2026 in China's infliximab market.

Sales volume and value of infliximab in China are expected to decline in 2022 as the Chinese government implements a strict "COVID-19 dynamic zeroing" policy that will prevent many healthcare facilities in China from operating normally. It is expected that the Chinese government will relax the COVID-19 control policy from early 2023 onwards, and thus the sales volume and sales value of infliximab in China will show a recovery growth from 2023-2026.

Topics covered:

• The impact of COVID-19 on China's Infliximab market

• Sales value of China's Infliximab 2017-2021

• Competitive landscape of China's Infliximab market

• Prices of Infliximab in China

• Prices of Infliximab in China by regions and manufacturers

• Analysis on factors affecting the development of China's Infliximab market

• Prospect of China's Infliximab market from 2022 to 2026

Table of Contents

1 Relevant Concepts of Infliximab

• 1.1 Indications for Infliximab
• 1.2 Development of Infliximab in China
• 1.3 Governmental Approval of Infliximab in China
• 1.4 The Impact of COVID-19 on Infliximab sales in China

2 Sales of Infliximab in China, 2017-2021

• 2.1 Sales Value of Infliximab
  • 2.1.1 Overall Sales Value
  • 2.1.2 Sales Value by Region
• 2.2 Sales Volume of Infliximab
  • 2.2.1 Overall Sales Volume
  • 2.2.2 Sales Volume by Regions
• 2.3 Sales of Infliximab by Dosage Form in China, 2017-2021
  • 2.3.1 Injection
  • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Infliximab Manufacturers in China, 2017-2021

• 3.1 Analysis of Market Share of Major Infliximab Manufacturers
  • 3.1.1 Investigation on Market Share by Sales Value
  • 3.1.2 Investigation on Market Share by Sales volume
• 3.2 Janssen Biologics BV
  • 3.2.1 Enterprise Profile
  • 3.2.2 Sales of REMICADE (Janssen's Infliximab) in China

4 Prices of Infliximab for Different Manufacturers in China, 2021-2022

• 4.1 Janssen Biologics BV (REMICADE)

5 Prospect of Chinese Infliximab drug Market, 2022-2031

• 5.1 Influential Factors of Chinese Infliximab Market Development
  • 5.1.1 The Impact of COVID-19 on Chinese Infliximab Market
  • 5.1.2 Market Drivers and Opportunities
  • 5.1.3 Market Threats and Challenges
• 5.2 Forecast on Market Size
• 5.3 Forecast on Market Trend

List of Charts

• Chart Infliximab Drugs Approved by Chinese Government, by 2022
• Chart Sales Value of Infliximab in China, 2017-2021
• Chart Sales Value of Infliximab in Regions of China, 2017-2021
• Chart Sales Volume of Infliximab in China, 2017-2021
• Chart Sales Volume of Infliximab in Regions of China,2017-2021
• Chart Sales value and volume of infliximab injection in China 2017-2021
• Chart Market Share of TOP3 Infliximab Manufacturers by Sales Value in China, 2017-2021
• Chart Market Share of TOP3 Infliximab Manufacturers by Sales Volume in China, 2017-2021
• Chart Profile of Janssen Biologics BV
• Chart Sales Value of Janssen Biologics BV 's Infliximab in China, 2017-2021
• Chart Sales Volume of Janssen Biologics BV 's Infliximab in China, 2017-2021
• Chart Profile of Taizhou Mabtech Pharmaceutical Co., Ltd.
• Chart Sales Value of Taizhou Mabtech Pharmaceutical Co., Ltd.'s Infliximab in China, 2017-2021
• Chart Sales Volume of Taizhou Mabtech Pharmaceutical Co., Ltd. 's Infliximab in China, 2017-2021
• Chart Hisun Biopharmaceutical Co., Ltd.
• Chart Sales Value of Xi'an Hanfeng Pharmaceutical Co., Ltd.'s Infliximab in China, 2017-2021
• Chart Sales Volume of Xi'an Hanfeng Pharmaceutical Co., Ltd.'s Infliximab in China, 2017-2021
• Chart Prices of Janssen Biologics BV's Infliximab (Remicade ®) in Parts of China, 2021-2022
• Chart Prices of Taizhou Mabtech Pharmaceutical Co., Ltd.'s Infliximab (Leiting®) in Parts of China, 2021-2022
• Chart Prices of Hisun Biopharmaceutical Co., Ltd.'s infliximab(Anbaite®) in Parts of China, 2021-2022
• Chart Forecast on sales of infliximab in China 2022-2031